ABSTRACT Highly purified platelet glucose;--phosphate dehydrogenase (G6PD; D-glucose-6phosphate:NADP+ 1-oxidoreductase, EC 1.1.1.49) can be modified in its isoelectric point and its molecular specific activity by extracts of some leukemic granulocytes. The "G6PD modifying factors" are relatively small molecules (molecular weight slightly under 5000), thermostable, dialyzable, and ultrafilterable. These molecules are destroyed by various endo-and exopeptidases and by serine enzymes present in crude extracts of leukocytes and commercial preparations of ribonuclease. The alterations of platelet G6PD due to the "G6PD modifying factors" are stable and not reversible by dialysis or further chromatography.
The chemical nature of such modifications and their relationships with post-translational modifications which occur in leukemic or normal cells are discussed.
Once synthesized, human glucose-6-phosphate dehydrogenase (G6PD; D-glucose-6-phosphate:NADP+ 1-oxidoreductase, EC 1.1.1.49) undergoes modifications of its molecular specific activity, isoelectric point, and kinetic properties (1, 2) . In erythrocytes, these modifications depend on the average age of the G6PD molecules and therefore on the age of the erythrocytes, since these cells no longer synthesize proteins (1) (2) (3) . However, the age of the enzyme molecules is not the only factor involved in these post-translational modifications; these alterations are also the result of an active process requiring tissue factors, whose concentration varies from one cell type to another.
We showed previously that some leukemic granulocytic cells have modified G6PD forms (4) (Fig. 1) . The leukemic extracts, when incubated with normal partially purified G6PD, led to modifications of this enzyme identical to those of the enzyme in the leukemic cell itself (4) . These results suggested that the modified forms of G6PD in leukemic cells were due to the high concentration of "G6PD modifying factors."
The purpose of this work was to characterize the biochemical nature of the "G6PD modifying factors," to elucidate the type of interaction between these factors and the enzyme, and, finally, to look for an effect of these factors on enzymes other than G6PD. MATERIAL AND studies were performed according to previously reported methods (2) . RNase activity was assayed according to Anfinsen et al. (6) .
Purification of Human Platelet G6PD. Human blood platelets suspended in citrate-dextrose were obtained, from the Centre National de Transfusion Sanguine-Paris. The remaining erythrocytes and leukocytes were eliminated by one centrifugation for 20 min at 300 X g at 40 and by two centrifugations for 2 min at 600 X g. The platelets were lysed by digitonin at saturation, and G6PD was then highly purified according to the method of Kahn and Dreyfus (7). About 0.7 mg of G6PD was obtained, with specific activity of 173 international units (IU)/mg of proteins. The overall yield was 56%. Platelet G6PD was homogeneous when tested by acrylamide-sodium dodecyl sulfate electrophoresis and immunodiffusion.
Electrofocusing on 7.5% acrylamide-2% Ampholine of pH range 3.5-10 and starch gel electrophoresis in Tris-borate buffer, pH 8, were described in previous papers; the gels were specifically stained for G6PD activity (2, 8) .
Studies of the In Vitro Modifications of Platelet G6PD by Leukemic "G6PD Modifying Factors." Ten microliters of purified G6PD dilution (total activity: 10 X 10-3 IU)
were mixed with the factors studied in 50 Al of 50 mM sodium phosphate buffer, pH 6.4, containing 2 mg/ml of bovine albumin, 0.2 mM NADP+, 1 mM dithiothreitol, 1 mM EDTA, 10 mM e-aminocaproic acid, and 1 mM diisopropylfluorophosphate; then, the preparation was protected from air by a coat of paraffin oil and incubated for 18 or 42 hr at 370. A 50 ul sample of the incubated mixture was deposited on the acrylamide-Ampholine columns for electrofocusing. In some experiments the influence of pH on the alterations of platelet G6PD by the leukemic "G6PD modifying factors" was studied in Tris chloride buffer pH 8 and pH 9.
Studies on Some Physicochemical Properties of the Leukemic "G6PD Modifying Factors." The leukemic extracts were prepared from the blood of two patients: one with chronic granulocytic leukemia and the other with acute myelocytic leukemia. G6PD from the leukemic granulocytes of these patients showed very abnormal electrofocusing patterns (4), with active bands of lower isoelectric point (Fig.  1) . The crude granulocyte extracts were prepared in 5 mM sodium phosphate buffer, pH 6.4, then either heated for 1 hr at 600 or boiled for 5 min, and ultrafiltered. The ultrafiltrate was concentrated by lyophilization, and then deposited on the top of a Sephadex G-25 column (80 X 2 cm) previously equilibrated with 5 mM phosphate buffer, pH 6.4. The flow rate was 10 ml/hr and fractions of 4 ml were collected. Each fraction was individually Iyophilized and tested against purified platelet G6PD.
Attempts were made to inactivate the "G6PD modifying factors" by proteases, phosphoesterases, nucleases, or neuraminidase.
The boiled and ultrafiltered leukemic extracts were incubated for 18 buffer, pH 7.5, containing 20 mM EDTA; 1 mg/ml of deoxyribonuclease from bovine pancreas in 50 mM phosphate buffer, pH 6.4, containing 10 mM MgCl2; 1 mg/ml of alkaline phosphatase in 100 mM NaOH-glycine buffer, pH 10; 2.5 mg/ml of acid phosphatase in 200 mM acetate buffer, pH 5.6; 1 mg/ml of neuraminidase from Vibrio cholerae in 200 mM citrate buffer, pH 5.4. After the incubation, the pH was adjusted to pH 6.4 with diluted HC1 or NaOH, the protein reagents were eliminated by ultra-filtration, and the ultrafiltrates were then incubated with purified platelet G6PD as described above. An attempt was made to inactivate the leukemic G6PD modifying factors by 2 mM iodoacetic acid at pH 4.6 and iodoacetamide at pH 8. After incubation overnight with these reagents, pH was adjusted to 6.4 and the reagents in excess were neutralized with 10 mM dithiothreitol.
Studies on the Influence of the "G6PD Modifying Factors" on Enzymes Other Than G6PD. Human leukocyte pyruvate kinase (A. Kahn, J. Marie, and P. Boivin in preparation) glucose-6-phosphate isomerase (0. Bertrand, A. Kahn, and P. Boivin in preparation) and 6-phosphogluconate dehydrogenase (9) were highly purified according to methods reported elsewhere. These purified enzymes were incubated at pH 6.4 with boiled and ultrafiltered leukemic granulocyte extracts in the same way as for G6PD. After incubation the residual enzyme activities were assayed and the modifications of electrophoretic mobility were examined by electrofocusing in plates of 3.75% acrylamide and 1.4% Ampholines of pH range 9-6 for pyruvate kinase, by electrofocusing in columns of 5% acrylamide-1% Ampholines of pH range [9] [10] [11] for glucose phosphate isomerase, and by starch gel electrophoresis for 6-phosphogluconate dehydrogenase.
RESULTS
Highly purified platelet G6PD showed upon electrofocusing one predominant active band (band a), with a minor more anodic band, (band b) (Fig. 2) . When incubated with either the boiled and ultrafiltered leukemic leukocyte extracts or the extracts heated for 1 hr at 600 with 1 mM diisopropylfluorophosphate, this pattern was changed into more anodic forms (Fig. 2) and simultaneously the enzymatic activity decreased 40-60% (Table 1) .
By contrast the extracts were left without any influence on platelet G6PD when heated for 1 hr at 60°without diisopropylfluorophosphate. Similarly a previous dialysis abolished the capacity of the extracts to modify platelet G6PD (Table 1) . Fig. 2 shows the influence of pH on the modifications of platelet G6PD by the boiled and ultrafiltered extract: the enzyme was modified at pH 6.4, hardly changed at pH 8, and unmodified at pH 9. After filtration of the boiled, ultrafiltered and lyophilized extracts on a Sephadex G-25 column, the fraction able to modify platelet G6PD was found just after the void volume of the column (Fig. 3 ). The more negative charge of modified C6PD led to an abnormal starch gel electrophoretic mobility (Fig. 5) . However, the differences between modified and unmodified platelet G6PD were less obvious in starch gel electrophoresis than in electrofocusing. The 1 2 3 4 5 6 7 8 FIG. 4 . Inactivation of the "G6PD modifying factors" in various conditions. Before incubation with purified platelet G6PD, the leukemic extracts were treated by: 1, buffer alone; 2, papain; 3, elastase; 4, trypsin; 5, chymotrypsin A; 6, RNase from bovine pancreas; 7, RNase Ti; 8, RNase from bovine pancreas in the presence of 2 mM diisopropylfluorophosphate.
for a crude extract of leukocyte G6PD incubated in vitro, and for the hyperanodic G6PD forms isolated by electrofocusing (2) . The main characteristics of the modified enzyme were a high Michaelis constant for glucose-6-phosphate (about 100 MM). As previously reported (2), molecular specific activity was decreased to 40-60% of normal. Table 2 shows the influence of the boiled and ultrafiltered leukemic extracts on other enzymes: glucose phosphate isomerase was drastically inactivated; leukocyte pyruvate kinase was stabilized and its isoelectric point was decreased; 6-phosphogluconate dehydrogenase showed a more anodic migration.
DISCUSSION
Platelet G6PD was purified and used to test the capacity of leukemic factors to modify G6PD because normal platelets have been shown to be very poor in G6PD modifying factors (2) .
The G6PD modifying factors were extracted from leukemic granulocytes in which G6PD itself had enzymatic forms with decreased isoelectric point. This finding seems to indicate that these factors are responsible, at least in part, for the abnormal electrofocusing pattern found in freshly extracted leukocytes. There were, however, differences between the in vivo and in vitro modifications of G6PD: in this latter case there were no intermediate forms between the initial band a and the hyperanodic bands, while in dvo molecular aging led to the transition: band a --band b -a band c -0 hyperanodic forms (2, 8) . Either the mechanism of the above transition is different from the transformation into hyperanodic forms, or the effects of the same G6PD modifying factors are different in vivo and in vitro.
The post-translational modifications of G6PD do not seem to be qualitatively different in either normal or leukemic leukocytes but only much faster in the latter cells than in the former ones. Consequently it is probable that the leukemic "G6PD modifying factors" are nearly, if not entirely, identical to the physiological factors, and that they exist in a much higher concentration.
These factors are molecules of low molecular weight, since they are dialyzable and ultrafilterable. The gel filtration experiment on a Sephadex G-25 column showed that their molecular weight was slightly below the limit of exclu- (14) . sion of the gel, i.e., below 5000. It seemed contradictory that the G6PD modifying factors were not destroyed by boiling but by heating of the leukocyte extracts for 1 hr at 60°.
The fact that diisopropylfluorophosphate protected the modifying factors against heating at 600 probably explained this apparent contradiction: at 600 the "modifying factors" would be not destroyed by heat, but by a serine enzyme inhibited by diisopropylfluorophosphate. The G6PD modifying factors were insensitive to the action of various proteases with narrow specificity, of neuraminidase, monophosphoesterases, deoxyribonuclease, and SH or imidazole reagents. By contrast they were inactivated by pepsin, bromelain, papain, carboxypeptidases B and C, and ribonuclease preparations. However, the action of ribonucleases was abolished by diisopropylfluorophosphate, although they are not serine enzymes (10); moreover, boiling for 15 min at pH 2.2 which did not inactivate pancreatic RNase, in agreement with Kunitz (11) , abolished the capacity of the commercial preparation to destroy the "G6PD modifying factors." These data indicated that the "modifying factors" were not destroyed by ribonucleases themselves, but by a serine enzyme contained in the ribonuclease preparations.
Thus the G6PD modifying factors are small thermostable molecules, destroyed by serine enzyme present in the leukocyte extracts and in the ribonuclease preparations, and destroyed also by various endo-and exopeptidases. These molecules seem to be, at least in part, oligopeptides, the terminal residue of which was partially elucidated by the action of the various carboxypeptidases: the "G-6PD modifying factors" have a COOH-terminal residue with a free carboxyl group, since carboxypeptidases B and C were active (12, 13) ; this COOH-terminal residue seems to be either L-lysine, Larginine, or L-ornithine, specifically removed by carboxypeptidase B (13) and slowly or not removed by carboxypeptidase A (13) .
Up to now the interactions between G6PD and modifying factors remain unknown. Obviously a nonenzymatic phenomenon is involved. Two hypotheses can be made: the first one is that all or part of the modifying factors bind to special groups of the enzyme. The ionization state of these groups would be involved in this binding. The second hypothesis is that the "modifying factors" are nonenzymatic catalysts of an alteration of the G6PD molecule itself. In any. case, the modifications of G6PD were stable and not reversible by the usual methods.
It is interesting to note that leukemic granulocyte extracts, boiled and ultrafiltered, were able to modify the electric charge and (or) the enzymatic activity of various other purified enzymes. Therefore, these alterations of enzymes by factors abundant in some leukemic cells may be a common phenomenon. The chemical nature of this phenomenon and the consequences of such enzyme alterations on the function of the leukemic cell remain to be determined. The possible relations of the leukemic factors to the physiological factors involved in molecular aging deserves to be explored.
